Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.11 USD | -0.41% | -10.50% | -44.40% |
Financials (USD)
Sales 2024 * | 370K | Sales 2025 * | 330K | Capitalization | 773M |
---|---|---|---|---|---|
Net income 2024 * | -230M | Net income 2025 * | -266M | EV / Sales 2024 * | 838 x |
Net cash position 2024 * | 462M | Net cash position 2025 * | 625M | EV / Sales 2025 * | 448 x |
P/E ratio 2024 * |
-3.27
x | P/E ratio 2025 * |
-3.09
x | Employees | 94 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.26% |
Latest transcript on Viridian Therapeutics, Inc.
1 day | -0.41% | ||
1 week | -10.50% | ||
Current month | -8.67% | ||
1 month | -5.98% | ||
3 months | -38.25% | ||
6 months | -23.88% | ||
Current year | -44.40% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 37 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 234 M€ | +9.05% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 12.11 | -0.41% | 908,812 |
24-05-23 | 12.16 | -4.25% | 1,377,183 |
24-05-22 | 12.7 | -1.40% | 665,816 |
24-05-21 | 12.88 | -4.80% | 801,612 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.40% | 773M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.64% | 40.47B | |
-10.87% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- VRDN Stock